How much funding has Metsera raised?

Metsera has raised $505.0M in total funding, most recently a Series B round.

Who are Metsera's investors?

Metsera's investors include Pfizer Ventures, OrbiMed, ARCH Venture Partners, Jeito Capital, Frazier Life Sciences, Novo Holdings A/S.

Where is Metsera headquartered?

Metsera is headquartered in New York, New York, United States.

What industry is Metsera in?

Metsera operates in Biotech, Obesity.

Metsera

Acquired

Reducing the burden of obesity

New York, United States · Founded 2022 · $505.0M raised

Biotech

Obesity

Headquarters: New York, New York
Employees: 11–50
Founded: 2022
Business Model: Other

Website: metsera.com
Total Funding: $505.0M
Last Round: $215.0M Series BNov 2024
Rounds: 2

About

Metsera is a clinical-stage biotechnology company focused on developing next-generation oral and injectable nutrient-stimulated hormone (NuSH) therapies for obesity and metabolic diseases. Their portfolio aims to reduce barriers to adoption with improved scalability, potency, and tolerability. Now part of Pfizer following acquisition.

Summary

Metsera is a Biotech company based in New York, United States, founded in 2022. It has raised $505.0M in total across 2 rounds, most recently a $215.0M Series B round in Nov 2024. Investors include Pfizer Ventures, OrbiMed and ARCH Venture Partners.

LinkedIn X (Twitter)